Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry [2] Core Insights - The cosmetics and medical beauty sector has underperformed the market recently, with the Shenwan Beauty Care Index declining by 4.8% from March 13 to March 20, 2026, which is 0.7 percentage points worse than the Shenwan A Index [4][5] - Upcoming earnings reports from key companies such as Lin Qingxuan and Shangmei will be critical to monitor [4][10] - The report highlights the performance of major companies, noting that Aimeike's revenue for 2025 is projected at 2.453 billion yuan, a year-on-year decrease of 18.94% [11] Summary by Sections Industry Performance - The Shenwan Cosmetics Index fell by 3.4%, while the Shenwan Personal Care Index dropped by 4.4%, indicating varied performance within the sector [4][5] - The report notes that the beauty care sector is entering earnings season, with several companies set to announce their financial results [10] Company Highlights - Aimeike's 2025 performance shows a revenue of 2.453 billion yuan, down 18.94% year-on-year, with a net profit of 1.291 billion yuan, down 34.05% [11] - Juzi Biotechnology reported a slight revenue decline of 0.4% to 5.519 billion yuan, with a net profit decrease of 7.2% [11] - The report emphasizes the importance of product matrix improvement and collaboration for growth in Aimeike's future performance [12] Market Trends - The report indicates that the retail sales of cosmetics in China grew by 4.5% year-on-year in the first two months of 2026, outperforming overall retail growth [16] - The report also notes that the domestic market is seeing a shift towards local brands, with significant growth in market share for domestic products [23] Industry Dynamics - The report discusses the strategic partnership between L'Oréal and NVIDIA to enhance AI research in beauty products, reflecting a trend towards technological integration in the industry [20] - The competitive landscape is evolving, with domestic brands gaining ground against international players, particularly in the skincare segment [23]

Investment Rating - Investment rating for the social services industry is "Positive" (maintained) [1] Core Insights - The report highlights a significant recovery in the Hong Kong real estate market, with a notable increase in both transaction volume and value for new residential properties in February 2026 [5][25] - The duty-free sales in Hainan have shown steady growth, indicating a robust economic performance since the island's closure for trade [14][13] - The invisible orthodontics market is experiencing rapid growth, with strong potential for leading companies to expand internationally [42][56] Summary by Sections Duty-Free Sales - Hainan's duty-free sales reached 60.6 billion yuan in February 2026, a year-on-year increase of 14.7%, with shopping visits up by 13.3% [14][16] - The total import and export trade in Hainan amounted to 654.9 billion yuan, reflecting a year-on-year growth of 29.1% [13] Commercial Real Estate - In February 2026, Hong Kong's new residential property transaction volume surged by 100.8% year-on-year, with transaction value increasing by 142.5% [28][31] - The market is entering a phase of rising prices and volumes, with the leading developer, Sun Hung Kai Properties, capturing 23% of the market share [32][5] Health Food Sector (Wugu Mofang) - Wugu Mofang is projected to achieve a net profit of 260-265 million yuan in 2025, representing a growth of 38%-40% [38][41] - The company reported a significant increase in sales across its online platforms, with a year-on-year growth of 71.3% in February 2026 [41][43] Invisible Orthodontics - The global market for invisible orthodontics is expected to reach approximately 12.5 billion USD by 2024, with a compound annual growth rate (CAGR) of 23.7% over the next decade [42][44] - The Chinese market is projected to see a significant increase in new cases, with a focus on children and adolescents driving growth [49][56] Market Performance - The Hong Kong consumer services index increased by 0.42%, while the retail sector declined by 5.80% during the week of March 16-20, 2026 [61][62] - New consumption categories have shown strong performance, with notable gains in companies like Le Si Group and Bu Lu Ke [64][67]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights the launch of JD's cross-border e-commerce platform Joybuy in six European countries, marking a shift to comprehensive retail operations and emphasizing a self-operated model to enhance competitive differentiation [25][27] - The report suggests focusing on high-quality companies in sectors benefiting from emotional consumption themes, including gold jewelry, offline retail, cosmetics, and medical aesthetics [7][30][31] Industry Overview - The retail and social service indices reported a decline of 4.55% and 4.00% respectively during the week of March 16-20, 2026, with the retail index down 12.57% year-to-date [6][15] - The hotel and restaurant sector showed the smallest decline this week, while it has the highest growth year-to-date at 3.19% [18][20] Company-Specific Insights - Joybuy's self-operated model is expected to create a competitive edge through quality control and service reliability, with over 60 logistics warehouses established in Europe [27][28] - The report recommends several companies based on their growth potential: - **Old Puhuang**: Expected net profit growth of 226%-233% in 2025, driven by channel expansion and brand enhancement [32][41] - **Chao Hong Ji**: Anticipated net profit growth of 125%-175% in 2025, supported by differentiated product strength and multi-channel marketing [35] - **Mao Ge Ping**: Expected revenue growth of 31.3% in H1 2025, benefiting from its position as a high-end domestic cosmetics brand [35] - **Meili Tianyuan Medical Health**: Projected net profit growth of 34% in 2025, leveraging strong market positioning in high-end beauty [35] Market Dynamics - The report emphasizes the importance of adapting to consumer trends, with a focus on emotional value and innovative product safety in cosmetics and personal care [30][31] - Companies are encouraged to explore opportunities in the evolving landscape of cross-border e-commerce, particularly those with strong brand and supply chain capabilities [27][30]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 155.04 [7]. Core Insights - The company is expected to achieve revenue of RMB 2.453 billion in 2025, a year-on-year decrease of 18.94%, and a net profit attributable to the parent company of RMB 1.291 billion, down 34.05% year-on-year. This decline is attributed to the medical beauty industry entering a mature and regulated phase, leading to intensified competition and slowing growth [1][5]. - The company has a rich pipeline of products, with new approvals progressing steadily. The recent approval of a botulinum toxin product and the registration of minoxidil lotion are expected to contribute positively to future revenues [4][5]. - The company is actively expanding its product lines, particularly in the freeze-dried powder category, which has shown significant revenue growth. The introduction of new products is anticipated to create new growth points and potentially restore revenue growth in 2026 [2][5]. Summary by Sections Financial Performance - In 2025, the company reported a gross margin of 92.7%, a decrease of 1.95 percentage points year-on-year. The gross margin for solution products was 93.1%, and for gel products, it was 97.3% [3]. - The sales expense ratio increased to 15.8%, primarily due to higher personnel costs and increased expenses related to sales activities [3]. Product Sales Structure - The revenue from solution injection products was RMB 1.265 billion, down 27.48% year-on-year, accounting for 51.57% of total revenue. Gel injection products generated RMB 890 million, down 26.82%, making up 36.27% of total revenue. Freeze-dried powder injection products contributed RMB 208 million, accounting for 8.48% [2]. Pipeline and New Products - The company has made significant progress in its product pipeline, with several products entering the registration and approval stages. The approval of the botulinum toxin product is particularly noteworthy as it is the seventh compliant product of its kind approved in China [4]. Earnings Forecast and Valuation - The revenue forecast for 2026 is adjusted to RMB 2.829 billion, reflecting a growth of 15.33% year-on-year. The net profit forecast for 2026 is slightly reduced to RMB 1.422 billion, down 14.9% from previous estimates [5][11]. - The company is valued at a price-to-earnings ratio of 33 times, with a target price adjustment reflecting a premium rate [5].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company reported its 2025 performance, which met market expectations, with total revenue of 2.453 billion yuan, a year-on-year decrease of 18.94%, and a net profit attributable to shareholders of 1.291 billion yuan, down 34.05% year-on-year [4] - The company's gross margin slightly decreased to 92.7%, with a net profit margin of 53.1%, reflecting a decline due to rising expense ratios [6] - The company is expanding its product matrix, with new products expected to drive future growth, including a recently certified botulinum toxin product and other treatments for hair loss [6] Financial Data and Profit Forecast - The total revenue forecast for 2026 is 2.904 billion yuan, with a projected year-on-year growth rate of 18.4% [5] - The net profit forecast for 2026 is 1.445 billion yuan, with a corresponding PE ratio of 27 [5] - The company anticipates a gradual recovery in profitability, with net profits projected to reach 1.800 billion yuan by 2028 [5][6]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company reported its 2025 performance, which met market expectations, with total revenue of 2.453 billion yuan, a year-on-year decrease of 18.94%, and a net profit attributable to shareholders of 1.291 billion yuan, down 34.05% year-on-year [4] - The company's gross margin slightly decreased to 92.7%, a decline of 1.9 percentage points year-on-year, while the net profit margin fell to 53.1%, down 11.6 percentage points year-on-year [6] - The company is expanding its product matrix, with new products like freeze-dried powder injections contributing to revenue growth, and expects to open up performance space with a rich pipeline of new and in-development products [6] Financial Data and Profit Forecast - The company forecasts total revenue for 2026 to be 2.904 billion yuan, with a year-on-year growth rate of 18.4% [5] - The projected net profit for 2026 is 1.445 billion yuan, reflecting an 11.9% increase compared to 2025 [5] - The earnings per share (EPS) is expected to be 4.78 yuan for 2026, with a price-to-earnings (PE) ratio of 27 [5][7]

Investment Rating - The report indicates a positive investment outlook for the beauty industry, with a projected retail sales growth of 5.1% in 2025, outperforming the overall retail market by 1.4 percentage points [7]. Core Insights - The beauty market is experiencing a recovery, with significant growth expected in the second half of 2025, particularly in online sales channels like Tmall and Douyin, despite a slowdown in Douyin's growth rate [6][7]. - The report highlights a shift in consumer preferences towards premium and specialized products, with categories like color cosmetics and personal care showing stronger growth compared to skincare [12]. - The competitive landscape is evolving, with domestic brands accelerating their multi-brand strategies, leading to an anticipated increase in industry concentration [19]. Summary by Sections Beauty Market Overview - The beauty market is projected to achieve a retail sales figure of 465.3 billion yuan in 2025, with a year-on-year growth of 5.1% [7]. - Online platforms such as Tmall and Douyin are expected to see varying growth rates, with Tmall recovering due to instant retail dynamics, while Douyin's growth is stabilizing [6]. Category Trends - Color cosmetics and personal care categories are expected to grow faster than skincare, with online sales across multiple platforms reaching 487.1 billion yuan, a year-on-year increase of 8.7% [12]. - New brands in personal care are emerging successfully, with notable growth rates for brands like Canban and OFF&RELAX [12]. Promotional Events - The Double Eleven shopping festival in 2025 is projected to generate a gross merchandise volume (GMV) of 1.695 trillion yuan, reflecting a 14% increase from 2024 [15]. - E-commerce platforms are focusing on instant retail to drive growth, with stable performance across various beauty categories during promotional periods [15]. Company Trends - Leading companies are rapidly developing multi-brand matrices, enhancing their operational capabilities and market presence [19]. - Companies like Shiseido and L'Oréal are showing signs of recovery in the high-end segment, while domestic brands are experiencing varied growth rates [31]. Medical Aesthetics - The medical aesthetics sector is seeing increased penetration, but competitive pressures are leading to price reductions [22]. - The report notes a shift from single-product offerings to more comprehensive product combinations in response to market demands [27]. Competitive Landscape - The beauty market is experiencing a K-shaped recovery, with high-end brands rebounding while mid-range brands face challenges [34]. - The report emphasizes the importance of brand strength and cost-effectiveness as key competitive factors in the current market environment [38].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue decline of 18.9% year-on-year for 2025, with a net profit decrease of 34.1%. The revenue for 2025 was 2.453 billion yuan, and the net profit was 1.291 billion yuan. The fourth quarter alone saw a revenue of 588 million yuan, down 9.6%, and a net profit of 198 million yuan, down 46.9% [5] - The forecast for net profit for 2026-2028 is adjusted to 1.515 billion yuan, 1.707 billion yuan, and 1.865 billion yuan respectively, with corresponding EPS of 5.01 yuan, 5.64 yuan, and 6.16 yuan. The current stock price corresponds to a PE of 27.7, 24.6, and 22.5 times for the years 2026-2028 [5] - The company has a rich product matrix and is expanding its international channels, which is expected to drive future growth. The valuation is considered reasonable, hence the "Buy" rating is maintained [5] Financial Summary - In 2025, the company's solution products generated revenue of 1.265 billion yuan (down 27.5%) with a gross margin of 93.1%. Gel products generated 890 million yuan (down 26.8%) with a gross margin of 97.3%. The newly added lyophilized powder injection products generated 208 million yuan, accounting for 8.5% of total revenue [6] - The overall gross margin for 2025 was 92.7% (down 1.9 percentage points), and the net margin was 53.1% (down 11.6 percentage points) due to intensified industry competition [6] - The company's operating expenses for 2025 were 15.8% for sales, 7.4% for management, and 14.7% for R&D, reflecting increases of 6.6 percentage points, 3.3 percentage points, and 4.7 percentage points respectively [6] Product and Channel Development - The product line is expected to grow steadily, with new approvals such as the A-type botulinum toxin "Orange Toxin" in January 2026, creating a one-stop aesthetic solution for facial aesthetics [7] - The company is enhancing its domestic sales channels and has expanded its international presence through the acquisition of REGEN, covering markets in dozens of countries [7]

Core Viewpoint - The company reported a significant decline in both revenue and net profit for 2025, indicating challenges in demand and increased competition in the market [4][5]. Financial Performance - In 2025, the company achieved a revenue of 2.45 billion yuan, down 18.9% year-on-year, and a net profit of 1.29 billion yuan, down 34.1% year-on-year [4]. - Quarterly breakdown for 2025 shows revenues of 660 million, 640 million, 570 million, and 590 million yuan for Q1 to Q4, with year-on-year declines of 17.9%, 25.1%, 21.3%, and 9.6% respectively [4]. - Net profits for the same quarters were 440 million, 350 million, 300 million, and 200 million yuan, with declines of 15.9%, 41.7%, 34.6%, and 46.9% respectively [4]. Product Performance - Revenue from solution products and gel products in 2025 was 1.26 billion and 890 million yuan, down 27.5% and 26.8% year-on-year respectively [5]. - Sales volumes for these products were 512,300 and 69,600 units, reflecting declines of 19.3% and 22.1% year-on-year [5]. - Average prices for solution and gel products were 247 yuan and 1,277 yuan per unit, down 10.2% and 6.1% year-on-year respectively [5]. Profitability and Cost Structure - The company's gross margin decreased by 1.9 percentage points to 92.7% in 2025, while the net profit margin fell by 12.1 percentage points to 52.6% [6]. - In Q4 2025, the gross margin was 90.6%, down 3.4 percentage points year-on-year, and the net profit margin was 33.7%, down 23.6 percentage points year-on-year [6]. - The increase in expense ratio by 16.0 percentage points to 38.2% was noted, with sales, management, R&D, and financial expense ratios rising significantly [7]. Strategic Developments - The company has made significant strides in the regenerative and botulinum toxin markets, including the acquisition of REGEN Biotech, Inc. and the launch of new products [8]. - The introduction of the "Hutox" botulinum toxin product is expected to enhance revenue, with projected annual contributions of up to 600 million yuan based on a 90% gross margin [8]. - The diversification of product offerings is anticipated to strengthen the company's market position and profitability through synergistic effects [8].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company reported a revenue of 2.45 billion yuan in 2025, a year-on-year decrease of 18.9%, and a net profit attributable to shareholders of 1.29 billion yuan, down 34.1% year-on-year [5] - The decline in performance is attributed to weak demand and increased competition, although the revenue drop in Q4 2025 has narrowed [6] - The company has made significant progress in the regenerative and botulinum toxin sectors, enhancing its product portfolio and market position [9] - Despite short-term challenges, the company has a robust pipeline of new products and is expected to benefit from the introduction of new offerings [10] Financial Performance Summary - In 2025, the company's revenue by product category was 1.26 billion yuan for solution products and 0.89 billion yuan for gel products, with respective year-on-year declines of 27.5% and 26.8% [6] - The gross margin decreased by 1.9 percentage points to 92.7%, while the net profit margin fell by 12.1 percentage points to 52.6% [7] - The company’s operating expenses increased by 16.0 percentage points to 38.2% in 2025, driven by higher sales and management costs [8] Product Development and Market Position - The company has diversified its product offerings, successfully acquiring REGEN Biotech, Inc. and launching new products in the regenerative and botulinum toxin categories [9] - The approval of the botulinum toxin product Hutox® is expected to contribute significantly to revenue, with potential annual sales of up to 600 million yuan [9] - The company’s strategy to enhance its product mix and leverage existing distribution channels is anticipated to strengthen its competitive edge [10] Earnings Forecast - The report projects a slight decrease in net profit forecasts for 2026 and 2027 to 1.45 billion yuan and 1.68 billion yuan, respectively, with an introduction of a new forecast for 2028 at 2.13 billion yuan [10] - The expected earnings per share (EPS) for 2026, 2027, and 2028 are 4.78 yuan, 5.56 yuan, and 7.04 yuan, respectively [10]